» Articles » PMID: 26076990

Characterization of Cardiac Amyloidosis by Atrial Late Gadolinium Enhancement Using Contrast-Enhanced Cardiac Magnetic Resonance Imaging and Correlation With Left Atrial Conduit and Contractile Function

Overview
Journal Am J Cardiol
Date 2015 Jun 17
PMID 26076990
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

The diagnosis of cardiac amyloidosis (CA) often necessitates invasive myocardial biopsy. We sought to evaluate whether late gadolinium enhancement (LGE) of the atrial myocardium by cardiac magnetic resonance imaging was associated with impaired left atrial (LA) function and whether the extent of LA LGE may enhance diagnostic differentiation of CA from other cardiomyopathies. Twenty-two patients with biopsy-proven CA, 37 with systemic hypertension (SH), and 22 with nonischemic dilated cardiomyopathy (NIDC) underwent cardiac magnetic resonance imaging and echocardiographic evaluation. Patients with CA had greater minimal LA volume (57 ± 53 vs 24 ± 18 in SH and 19 ± 25% in NIDC, p = 0.003), and significantly lower total LA emptying function (19 ± 14 vs 40 ± 14 in SH and 33 ± 20% in NIDC, p = 0.0006). The mean proportion of atrial enhancement (LGELA%) was significantly greater in patients with CA than with SH and NIDC (59 ± 36% vs 7.4 ± 2.1 and 2.9 ± 9.0%, p <0.0001, respectively). There was also a strong inverse correlation between both active and total atrial emptying (r = -0.69, p = 0.001; r = -0.67, p = 0.01, respectively) with LGELA% for patients with CA. In multivariate regression analysis, LGELA% was the strongest adjusted predictor for CA diagnosis. Using receiver operating characteristic analysis, LGELA% ≥33% produced the greatest diagnostic utility for CA (sensitivity 76%, specificity 94%). Patients with CA may have extensive LGE of the LA myocardium, which is associated with marked reduction in LA emptying function. The extent of LA LGE was highly predictive for the diagnosis of CA.

Citing Articles

Atrial Lesion and Diastolic Dysfunction May Be Associated With Atrial Fibrillation in Patients With Cardiac Amyloidosis.

Otsuka K, Kawano H, Koike H, Sueyoshi E, Arakawa S, Fukae S Circ Rep. 2024; 6(12):539-546.

PMID: 39659638 PMC: 11626019. DOI: 10.1253/circrep.CR-24-0116.


Current Perspectives on Atrial Amyloidosis: A Narrative Review.

Tana M, Tana C, Guglielmi M, Stefanelli A, Mantini C, Porreca E Rev Cardiovasc Med. 2024; 25(2):73.

PMID: 39077357 PMC: 11263142. DOI: 10.31083/j.rcm2502073.


A Novel Approach to Cardiac Magnetic Resonance Scar Characterization in Patients Affected by Cardiac Amyloidosis: A Pilot Study.

Alfieri M, Guerra F, Lofiego C, Fogante M, Ciliberti G, Vagnarelli F Medicina (Kaunas). 2024; 60(4).

PMID: 38674259 PMC: 11051713. DOI: 10.3390/medicina60040613.


CMR-based right ventricular strain analysis in cardiac amyloidosis and its potential as a supportive diagnostic feature.

Eckstein J, Korperich H, Weise Valdes E, Sciacca V, Paluszkiewicz L, Burchert W Int J Cardiol Heart Vasc. 2023; 44:101167.

PMID: 36632287 PMC: 9827025. DOI: 10.1016/j.ijcha.2022.101167.


Cardiovascular Magnetic Resonance Imaging-Based Right Atrial Strain Analysis of Cardiac Amyloidosis.

Eckstein J, Sciacca V, Korperich H, Paluszkiewicz L, Weise Valdes E, Burchert W Biomedicines. 2022; 10(12).

PMID: 36551760 PMC: 9775378. DOI: 10.3390/biomedicines10123004.


References
1.
Austin B, Tang W, Rodriguez E, Tan C, Flamm S, Taylor D . Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging. 2010; 2(12):1369-77. DOI: 10.1016/j.jcmg.2009.08.008. View

2.
Sun J, Stewart W, Yang X, Donnell R, Leon A, Felner J . Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol. 2009; 103(3):411-5. DOI: 10.1016/j.amjcard.2008.09.102. View

3.
Wassmuth R, Abdel-Aty H, Bohl S, Schulz-Menger J . Prognostic impact of T2-weighted CMR imaging for cardiac amyloidosis. Eur Radiol. 2011; 21(8):1643-50. DOI: 10.1007/s00330-011-2109-3. View

4.
Mohty D, Pibarot P, Dumesnil J, Darodes N, Lavergne D, Echahidi N . Left atrial size is an independent predictor of overall survival in patients with primary systemic amyloidosis. Arch Cardiovasc Dis. 2011; 104(12):611-8. DOI: 10.1016/j.acvd.2011.10.004. View

5.
Liu D, Hu K, Niemann M, Herrmann S, cikes M, Stork S . Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013; 6(6):1066-72. DOI: 10.1161/CIRCIMAGING.113.000683. View